| Title |
Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action
|
|---|---|
| Published in |
Drug Safety, August 2018
|
| DOI | 10.1007/s40264-018-0708-5 |
| Pubmed ID | |
| Authors |
Anna Radecka, Louise Loughlin, Mick Foy, Margarida Viana de Ferraz Guimaraes, Viola Macolic Sarinic, Marina Dimov Di Giusti, Marina Lesicar, Sabine Straus, Dolores Montero, Julia Pallos, Jelena Ivanovic, June Raine |
| Abstract |
In November 2013, a team of European regulators initiated the Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) Joint Action. Funded by the Health Programme of the European Union, and with contributions from the involved Member States, SCOPE gathered information and expertise on how regulators in Member States run their national pharmacovigilance systems to meet the requirements of the pharmacovigilance legislation that came into effect in June 2012. The SCOPE project evaluated then-current practices and developed tools to further improve the skills and capability in the pharmacovigilance network. The project was divided into eight separate work streams, five of which concentrated on pharmacovigilance topics-collecting information on suspected adverse drug reactions, identifying and managing safety issues (signals), communicating risk and assessing risk minimisation measures, supported by effective quality management systems. The other three work streams focused on the functional aspects-coordination, communication and evaluation of the project. Through the project, SCOPE delivered guidance, training in key aspects of pharmacovigilance, and tools and templates to support best practice. The deliverables provide practical guidance that those working in the European national competent authorities can take to strengthen their national systems. The SCOPE outputs can be useful for other stakeholders involved in pharmacovigilance activities, including the pharmaceutical industry, healthcare professionals, patient and consumer organisations, and academia. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 25% |
| Sweden | 1 | 25% |
| New Zealand | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Science communicators (journalists, bloggers, editors) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 62 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 15 | 24% |
| Student > Ph. D. Student | 6 | 10% |
| Student > Bachelor | 6 | 10% |
| Researcher | 3 | 5% |
| Student > Doctoral Student | 2 | 3% |
| Other | 7 | 11% |
| Unknown | 23 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 23% |
| Nursing and Health Professions | 8 | 13% |
| Medicine and Dentistry | 4 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Agricultural and Biological Sciences | 3 | 5% |
| Other | 7 | 11% |
| Unknown | 23 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 September 2018.
All research outputs
#13,271,448
of 23,100,534 outputs
Outputs from Drug Safety
#1,230
of 1,706 outputs
Outputs of similar age
#162,903
of 333,760 outputs
Outputs of similar age from Drug Safety
#16
of 27 outputs
Altmetric has tracked 23,100,534 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,706 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.8. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,760 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.